ILiAD Biotechnologies, LLC, a biotech company developing BPZE1, the most advanced next generation intranasal pertussis ...

Clinical trials company Hvivo has completed its first acquisition, buying two research units from German group CRS for €10 ...

Condition affects about 16m people per year, and accounts for about 160,700 deaths in children younger than five ...

Pharmaceutical services firm hVivo, formerly Open Orphan, has acquired two clinical trial units in Germany from CRS Clinical ...

Hvivo paid £10 million in cash for the takeover of CRS, a German clinical trial firm with two research units, marking the ...

For investors searching for shares to buy in February, this small UK firm might be worth considering for inclusion in a ...

VIVO, a fast-growing early-stage German contract research organization (CRO) has acquired two clinical research units from Clinical Research Services (CRS), in Mannheim and Kiel, Germany, for a total ...

(Alliance News) - hVIVO PLC on Wednesday released an optimistic pre-annual results trading update, and said it expects "further strong growth" next year. However, the stock was down 7.4% at 18.89 ...

hVIVO described the deal with ILiAD as a "landmark study" in its human challenge portfolio. This model of testing means researchers expose volunteers to the bacteria, rather than waiting to test ...

LONDON - hVIVO plc, a leading early-stage Contract Research Organisation (CRO) known for its human challenge clinical trials, has acquired two Clinical Research Units (CRUs) from CRS Clinical Research ...

This Warren Buffett-influenced fund manager reckons small-cap stocks are the way to go for risk-tolerant investors starting ...